AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1/Phase 2NCT04068610COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCMedImmune LLC · Metastatic Microsatellite-stable Colorectal CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04999969Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or...AstraZeneca · Locally Advanced or Metastatic Solid TumoursActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 7, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04745689Study of AZD2811 + Durvalumab in ES-SCLCAstraZeneca · Small-Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jun 18, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT07222917A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in...AstraZeneca · Chronic Kidney Disease and HypertensionActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 10, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT02519348A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced...MedImmune LLC · Hepatocellular CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 6, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT07128615A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)AstraZeneca · Influenza AActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 28, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT01081951Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With...AstraZeneca · Ovarian CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2011Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02180724An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaAcerta Pharma BV · Waldenström Macroglobulinemia (WM)Active, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 1, 2019Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03459846A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)AstraZeneca · Urinary Bladder NeoplasmsActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 15, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03837899Durvalumab and Tremelimumab for Pediatric MalignanciesAstraZeneca · Pediatric CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Feb 28, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05246514A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCAstraZeneca · HER2-mutant Non-Small Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Nov 4, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05941897A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic...AstraZeneca · Advanced or Metastatic NSCLCActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 29, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05374603Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCAstraZeneca · Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 18, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06151964A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With...AstraZeneca · Overweight and ObesityActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06271837A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsAstraZeneca · Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)Active, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Feb 10, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT07215702A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.AstraZeneca · SepsisRecruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Feb 11, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.